All sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. $1093.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS27
PHASE 3 / 2-313
RECRUITING9
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO0%

Delay Index: of 9 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open CSPC ZhongQi Pharmaceutical Technology Co., Ltd. on the live radar map → 📅 $1093.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SKLB1028 Dose Escalation
NCT05445154
P1/2RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)582024-10-31
Letrozole
NCT06957379
P2Active, not recruitingHR+/HER2- Advanced/Metastatic Breast Cancer782025-06
DP303c
NCT06313086
P3RecruitingHER2-positive Breast Cancer4422025-12
DP303c
NCT05901935
P3Not yet recruitingHER2-positive Advanced Breast Cancer4202026-01
SYH9056
NCT06771245
P3Not yet recruitingMild-to-moderate Essential Hypertension6062026-03-30
Docetaxel for Injection (Albumin bound)
NCT06492941
P3Not yet recruitingAdvanced Pancreatic Cancer1422026-04-14
Docetaxel for injection (Albumin-bound)
NCT06296706
P3RecruitingGastric Cancer6302026-06-01
HB1801
NCT07116824
P2Not yet recruitingHER2-positive Breast Cancer802026-07-15
Sirolimus for Injection (Albumin-bound)
NCT06929325
P3Not yet recruitingHR+/HER2- Advanced/Metastatic Breast Cancer3122026-10
Hydroxocobalamin Chloride Injection
NCT07163364
P3Not yet recruitingMethylmalonic Acidemia (MMA)202026-10-08
HB1801
NCT07083505
P2Not yet recruitingAdvanced Breast Cancer602026-10-11
Glumetinib tablets
NCT06525350
P2Not yet recruitingLocally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression2562026-12-25
Docetaxel for Injection (Albumin-bound)
NCT06136988
P1/2Not yet recruitingLocally Advanced Unresectable Esophageal Squamous Carcinoma1292027-04
SYH2085
NCT07798193
P2Not yet recruitingInfluenza2132027-04-30
Glumetinib Tablets
NCT06947291
P2RecruitingAdvanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors3502027-04-30
CM326 dose 1
NCT07418736
P2RecruitingChronic Obstructive Pulmonary Disease3182027-07-01
SYHX2008 injection
NCT06505395
P2RecruitingGastrointestinal Neuroendocrine Pancreatic Tumor902027-08-01
sirolimus (albumin-bound)
NCT07241936
P1/2RecruitingAdvanced Solid Tumors4442027-10-30
Sirolimus for injection (Albumin-bound)
NCT07684287
P2Not yet recruitingEpithelioid Hemangioendothelioma402027-11-30
Mitoxantrone Hydrochloride Liposome Injection
NCT04668690
P3Active, not recruitingPeripheral T Cell Lymphoma1932027-12-30
HB1801
NCT07805135
P3Not yet recruitingHER2-Negative Advanced Breast Cancer4302028-06-01
HA131
NCT07282509
P1/2Not yet recruitingAdvanced Hepatocellular Carcinoma (HCC)1162028-06-26
Sirolimus for injection (albumin bound)
NCT07165886
P2/3RecruitingGastroenteropancreatic Neuroendocrine Tumors2982028-08-29
SYH2051
NCT07911579
P1/2Not yet recruitingAdvanced Solid Tumors1542028-12-30
SYHX2008
NCT07623824
P3Not yet recruitingDiagnosed With Acromegaly, Currently in the Active Stage of the Disease1542029-07-31
CM310
NCT06547333
P2/3Not yet recruitingChronic Obstructive Pulmonary Disease8842032-04-29
CM310
NCT05761028
P2/3RecruitingModerate to Severe Asthma6002032-05